Zacks Investment Research on MSN: How will Mounjaro and Zepbound sales aid LLY's upcoming Q1 results? Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its blockbuster GLP-1 therapies, Mounjaro for type II diabetes (T2D) and Zepbound for obesity. Healthline: Mounjaro, Zepbound May Lower Risk of Eye Disease in People With Diabetes Mounjaro, Zepbound May Lower Risk of Eye Disease in People With Diabetes Eli Lilly and Co.

Context Explanation

reported fourth-quarter results Wednesday that topped Wall Street expectations, with revenue of $19.3 billion — up 43% from the same quarter a year ago, driven by growth in sales of ... Share on Pinterest Tirzepatide may help lower the risk of diabetic retinopathy, a diabetes complication that can lead to vision loss. Douglas Sacha/Getty Images Weight loss medications Mounjaro and ... The Globe and Mail: Public health plans should cover Mounjaro for Type 2 diabetes, Canada’s Drug Agency recommends Public health plans should cover the blockbuster drug Mounjaro for patients with type 2 diabetes, Canada’s Drug Agency says, as long as manufacturer Eli Lilly Split N/A N/A 08/29/22 N/A 08/29/22 N/A 1 ...

Insight Material